AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Alagille Syndrome

Recent research efforts aimed at curing Alagille Syndrome.

Last updated

Alagille Syndrome

Overview

Alagille syndrome (ALGS) is a rare, inherited multisystem condition caused mainly by having one nonworking copy of the JAG1 gene and less often by variants in NOTCH2, two components of the Notch cell-signaling pathway. It can affect the liver, heart and blood vessels, kidneys, eyes, skeleton, growth, and development; its hallmark liver problem is too few intrahepatic bile ducts, which can cause cholestasis (impaired bile flow), jaundice, severe itching, poor growth, vitamin deficiencies, fibrosis, and liver failure. Disease severity varies widely: some people have mild disease, while among those with neonatal cholestasis, about half undergo liver transplantation by age 18 in the large GALA natural-history cohort summarized by GeneReviews. Current care is multidisciplinary and includes nutritional and fat-soluble-vitamin support, management of heart, kidney, and vascular disease, medicines or surgery for itching and cholestasis, and liver transplantation for refractory cholestasis or end-stage liver disease.

There is no cure for ALGS as a whole. The approved ileal bile acid transporter (IBAT) inhibitors maralixibat and odevixibat lower the recycling of bile acids through the intestine and liver, reducing itching and circulating bile acids, but they do not repair the inherited signaling defect or reliably rebuild the missing bile-duct network. GeneReviews therefore still identifies transplantation—not a drug—as the definitive intervention for severe liver failure, while noting that transplantation cannot correct ALGS manifestations outside the liver.

Scope of Recent Research (2020–present)

Research activity has become meaningfully more translational since 2020: clinical development has improved bile-acid control and quality of life, while laboratory groups have shifted toward the more ambitious goal of restoring bile-duct development after birth. The dominant curative questions are whether partial restoration of Jagged/Notch signaling can regenerate a functional biliary tree, which cell types must be reached, and whether this can be done without harmful Notch activation elsewhere in the body. The strongest disease-modifying results remain in mice and zebrafish, so the field is closer to identifying plausible liver-directed regenerative treatments than to a human curative therapy.

Major Breakthroughs and Emerging Therapies

The most notable advance is a liver-directed gene-regulation strategy rather than replacement of JAG1 itself. In 2025, Fox and colleagues used a single early-life injection of an adeno-associated virus type 8 (AAV8) vector carrying an artificial microRNA that lowers Sox4 expression in mouse ALGS models. The treatment improved bile-duct-tree formation and produced durable improvements in liver structure and function, including when delivered after injury had started. This is important because it suggests that an underdeveloped biliary tree may retain some capacity for repair; however, it is preclinical, liver-focused, and does not correct the underlying JAG1 or NOTCH2 variant throughout the body.

A second regenerative strategy uses an antisense oligonucleotide (ASO)—a short synthetic strand of nucleic acid that reduces production of a chosen protein—to lower the glycosyltransferase POGLUT1. In three mouse models with ALGS-like bile-duct paucity, postnatal anti-Poglut1 ASO injections improved bile-duct formation, biliary-tree architecture, bilirubin, fibrosis, necrosis, and inflammatory changes. The investigators linked this rescue to increased JAG1 protein and JAG1-mediated signaling. This is a particularly relevant approach for JAG1 haploinsufficiency because it aims to amplify signaling from the remaining working copy rather than replace a large gene, but its safety, dosing window, delivery to the relevant liver cells, and applicability to NOTCH2-related ALGS remain unresolved.

Researchers have also tested direct pharmacologic enhancement of the Jagged/Notch/SOX9 pathway. In a zebrafish ALGS model and patient-derived fibroblasts, a small-molecule putative Notch agonist increased SOX9-related signaling, improved intrahepatic bile-duct development and cholestasis, and increased survival in mutant fish. This provided proof of concept that boosting a weakened developmental pathway could be therapeutic. The major caution is that Notch signaling is active in many tissues and is involved in cancer biology and normal development, making systemic activation a potentially high-risk strategy.

Direct JAG1 or NOTCH2 gene replacement and gene editing remain conceptually attractive but technically immature for ALGS. A 2021 therapeutic-development review noted that conventional AAV vectors have limited cargo capacity, whereas JAG1 and NOTCH2 exceed the approximate size that can be readily packaged in a single standard AAV vector. The review also highlighted the need to target multiple disease-relevant tissues and the possibility of immune and off-target effects. Consequently, recent work has emphasized pathway modulation and regenerative repair rather than clinical gene replacement or CRISPR editing.

Clinical Trials and Experimental Approaches

Recent human trials have primarily advanced symptom- and cholestasis-directed therapy, not cures. In the sponsor-funded phase 2b ICONIC study, children receiving maralixibat had durable reductions in serum bile acids and itching; during randomized withdrawal, switching to placebo worsened both outcomes, while gastrointestinal adverse events were common. The 2021 trial report supported the clinical role of IBAT inhibition, and FDA records show that maralixibat is approved in the United States for cholestatic pruritus in ALGS from 3 months of age.

Ipsen/Albireo’s phase 3 ASSERT trial of odevixibat enrolled 52 people with ALGS and found significantly greater improvement than placebo in caregiver-reported scratching and serum bile acids at 24 weeks; diarrhea was the most frequent treatment-emergent adverse event. The peer-reviewed ASSERT report and its completed ClinicalTrials.gov record establish efficacy for itch and bile-acid reduction, not biliary regeneration. Its phase 3 open-label extension, ASSERT-EXT, remains active but not recruiting as of its July 2, 2026 update, with estimated completion on December 31, 2026. The trial registry describes continued assessment of long-term safety and effectiveness.

Earlier intervention is also being studied. Mirum Pharmaceuticals’ open-label phase 2 RISE study tested maralixibat in infants younger than 12 months with ALGS or progressive familial intrahepatic cholestasis; the registry lists 27 enrolled participants and a December 17, 2024 completion date, but does not yet provide peer-reviewed efficacy results specific to ALGS infants. The RISE record is important because the regenerative window for bile-duct development may be earliest in life, although IBAT inhibition itself is not expected to reconstruct ducts.

Methodologies and Scientific Approaches

ALGS researchers use complementary models to determine whether a therapy can create patent, connected bile ducts rather than merely change liver-blood-test results. Mouse models with reduced Jag1 dosage enable measurement of bile-duct-to-portal-vein ratios, bile-tree branching, fibrosis, bilirubin, inflammation, and durability after ASO or AAV treatment. A three-dimensional imaging and analysis platform called DUCT showed that ALGS-model mice and human ALGS liver samples can have abruptly ending bile ducts, providing a structural endpoint for regenerative studies.

Human cellular platforms are becoming more sophisticated. Researchers have made patient-derived and CRISPR-engineered induced pluripotent stem cells (iPSCs), including JAG1-knockout iPSC lines, and differentiated iPSCs into three-dimensional hepatic organoids containing hepatocyte and cholangiocyte-like cells. These organoids reproduced effects of different JAG1 variants on liver development and can support variant testing, pathway studies, and screening for treatments that restore biliary differentiation before candidate therapies reach animals or patients.

Leading Institutions and Funding

Baylor College of Medicine, UMass Chan Medical School, and Cincinnati Children’s Hospital Medical Center are central to the recent regenerative liver work, collaborating on the AAV-SOX4 mouse study. The 2025 preclinical report builds on Baylor- and Cincinnati-associated work targeting POGLUT1 with ASOs, for which Ionis Pharmaceuticals supported ASO design, screening, and production. The POGLUT1 study also lists support from multiple National Institutes of Health grants, Baylor programs, and two Alagille Syndrome Accelerator Awards.

Clinical and natural-history research is organized internationally through the Global ALagille Alliance (GALA) study and specialist centers including the Children’s Hospital of Philadelphia, while Mirum Pharmaceuticals and Ipsen/Albireo have driven IBAT-inhibitor trials. The Alagille Syndrome Alliance launched its Scientific Research Network in 2024 and has funded a two-year, $150,000 Collaborative Scientific Research Grant program; its first listed award went to Stanford University School of Medicine for a project addressing bleeding risk in children with ALGS. The Alliance’s research-network description also describes smaller awards for drug screening and JAG1 variant-function research.

Strengths, Limitations, and Challenges

The field’s main strength is that multiple independent experimental approaches now converge on the same biological objective: increasing effective Jagged/Notch/SOX9 signaling sufficiently to form or repair bile ducts. ASO-mediated POGLUT1 reduction, small-molecule Notch enhancement, and AAV-mediated SOX4 reduction each improved bile-duct-related outcomes in animal models. Meanwhile, maralixibat and odevixibat have established practical biomarkers—itch scores and serum bile acids—and have reduced a major source of suffering in patients. The ASSERT trial provides high-quality randomized evidence for this symptomatic benefit.

The central limitation is translation. ALGS is a developmental, multisystem disease with great variability even among people carrying similar variants, so rescuing postnatal liver disease in a mouse may not repair heart, kidney, vascular, skeletal, or eye manifestations in people. Standard AAV gene replacement is complicated by the size of JAG1 and NOTCH2, while systemic pathway enhancement could cause unwanted effects in other organs. These vector-capacity and safety concerns are compounded by uncertainty about the latest effective treatment window, whether established fibrosis limits delivery or repair, and which patients—including those with NOTCH2 variants—would benefit. Access also remains a challenge: advanced genetic medicines and transplantation require highly specialized care, and approved IBAT inhibitors are chronic treatments rather than one-time cures.

Outlook and Future Directions

As of September 8, 2026, a human cure for Alagille syndrome is not close enough to predict a timeline, but the evidence for postnatal biliary repair has strengthened substantially. The most consequential milestones to watch are reproducibility of AAV-SOX4 and anti-POGLUT1 results in additional models, demonstration that treatment works after clinically meaningful liver injury and at clinically realistic ages, rigorous toxicology and biodistribution studies, and the first regulatory clearance for a human trial that measures bile-duct architecture and transplant-free liver survival rather than itching alone. If a liver-directed regenerative therapy proves safe and durable, it could eventually reduce transplantation; achieving a whole-body cure would likely require additional solutions for ALGS’s cardiac, vascular, renal, and other manifestations. Current evidence supports cautious optimism for disease modification, not a near-term cure.

References

Don't see your disease? Request a report